Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Operating Leases (2019 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Operating Leases for 7 consecutive years, with $20.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases fell 16.86% year-over-year to $20.8 million, compared with a TTM value of $20.8 million through Dec 2025, down 16.86%, and an annual FY2025 reading of $20.8 million, down 16.86% over the prior year.
  • Operating Leases was $20.8 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $21.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $32.2 million in Q2 2022 and bottomed at $4.1 million in Q1 2022.
  • Average Operating Leases over 5 years is $21.2 million, with a median of $25.5 million recorded in 2023.
  • The sharpest move saw Operating Leases fell 28.95% in 2022, then skyrocketed 619.42% in 2023.
  • Year by year, Operating Leases stood at $4.5 million in 2021, then surged by 571.17% to $30.2 million in 2022, then decreased by 14.26% to $25.9 million in 2023, then decreased by 3.51% to $25.0 million in 2024, then dropped by 16.86% to $20.8 million in 2025.
  • Business Quant data shows Operating Leases for ARCT at $20.8 million in Q4 2025, $21.9 million in Q3 2025, and $22.9 million in Q2 2025.